- Home
- IONS vs CCCS Comparison
IONS vs CCCS Comparison
Compare IONS & CCCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CCCS
- Stock Information
- Founded
- IONS 1989
- CCCS 1980
- Country
- IONS United States
- CCCS United States
- Employees
- IONS N/A
- CCCS N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CCCS Computer Software: Prepackaged Software
- Sector
- IONS Health Care
- CCCS Technology
- Exchange
- IONS Nasdaq
- CCCS Nasdaq
- Market Cap
- IONS 6.8B
- CCCS 5.9B
- IPO Year
- IONS 1991
- CCCS N/A
- Fundamental
- Price
- IONS $70.41
- CCCS $9.17
- Analyst Decision
- IONS Strong Buy
- CCCS Buy
- Analyst Count
- IONS 20
- CCCS 7
- Target Price
- IONS $75.55
- CCCS $11.29
- AVG Volume (30 Days)
- IONS 2.1M
- CCCS 5.3M
- Earning Date
- IONS 10-29-2025
- CCCS 10-30-2025
- Dividend Yield
- IONS N/A
- CCCS N/A
- EPS Growth
- IONS N/A
- CCCS N/A
- EPS
- IONS N/A
- CCCS 0.00
- Revenue
- IONS $944,050,000.00
- CCCS $996,961,000.00
- Revenue This Year
- IONS $24.02
- CCCS $13.57
- Revenue Next Year
- IONS $4.06
- CCCS $9.04
- P/E Ratio
- IONS N/A
- CCCS $3,081.86
- Revenue Growth
- IONS 16.05
- CCCS 9.60
- 52 Week Low
- IONS $23.95
- CCCS $8.14
- 52 Week High
- IONS $74.42
- CCCS $12.88
- Technical
- Relative Strength Index (RSI)
- IONS 63.48
- CCCS 48.02
- Support Level
- IONS $70.47
- CCCS $8.70
- Resistance Level
- IONS $74.42
- CCCS $9.15
- Average True Range (ATR)
- IONS 1.84
- CCCS 0.26
- MACD
- IONS -0.64
- CCCS 0.01
- Stochastic Oscillator
- IONS 37.12
- CCCS 55.36
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About CCCS CCC Intelligent Solutions Holdings Inc.
CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, and AI-enabled digital workflows. It operates in a single segment being Domestic segment which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in United States and China. Majority of the revenue is generated from United States.